SHARE

Anavex Life Sciences Corp (OTCMKTS:AVXL) biopharmaceutical company developing novel drugs to treat Alzheimer’s and other CNS diseases reported the appointment of Dr. Steffen Thomas, PhD, to company’s Board of Directors. Dr. Thomas holds PhD and MS degrees in Chemistry pursued from the University of Munich.

The details

Dr. Thomas brings fifteen years of extensive experience in patent law, proprietary technology rights and intellectual property to the company. He has considerable expertise in small molecule pharmaceuticals. He is currently a European trademark attorney, a patent attorney and European patent attorney at Epping Hermann Fischer, a known European intellectual property law entity. Previously, Dr. Thomas worked for Takeda Pharmaceutical Company, which is the largest pharmaceutical entity in Asia. Prior to that, he was associated with Nycomed Pharma, which was bought by Takeda in 2011 for almost USD $10 billion.

The practice

Anavex highlighted that Dr. Thomas’ legal practice comprises drafting of patent applications, challenging patent applications before international and national patent offices, challenging and defending patents in opposition, plea, and nullity proceedings. It also covers enforcing patents before the violation courts, and forming opinions on infringement and patentability in the technical field of chemistry. Christopher U. Missling, PhD, the CEO said that they are delighted to welcome Dr. Thomas on the Board. The management believes Dr. Thomas’ pharmaceutical industry insight and expertise in intellectual property will be extremely helpful as Anavex is advancing its product pipeline.

The highlights

This is the second major appointment by the company in last few months. In March, the company included Jacqueline French, MD, FAAN in its Scientific Advisory Board. Since the issuance of important PRs, Anavex Life Sciences Corp (OTCMKTS:AVXL) stock has been moving up on the charts.

In last trading session, the stock price of Anavex declined more than 3% to close the trading session at $0.419.The decline came at a share volume of 765,187 compared to average share volume of 1.24 million.

LEAVE A REPLY